These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25892482)

  • 1. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.
    Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR
    Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
    Moe SM; Chen NX; Newman CL; Organ JM; Kneissel M; Kramer I; Gattone VH; Allen MR
    J Bone Miner Res; 2015 Mar; 30(3):499-509. PubMed ID: 25407607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing.
    Agholme F; Macias B; Hamang M; Lucchesi J; Adrian MD; Kuhstoss S; Harvey A; Sato M; Aspenberg P
    J Orthop Res; 2014 Mar; 32(3):471-6. PubMed ID: 24243768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.
    Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR
    Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
    Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
    Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production.
    Liao HW; Huang TH; Chang YH; Liou HH; Chou YH; Sue YM; Hung PH; Chang YT; Ho PC; Tsai KJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.
    Allen MR; Chen NX; Gattone VH; Moe SM
    Am J Nephrol; 2013; 38(6):458-64. PubMed ID: 24280830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
    Newman CL; Creecy A; Granke M; Nyman JS; Tian N; Hammond MA; Wallace JM; Brown DM; Chen N; Moe SM; Allen MR
    Kidney Int; 2016 Jan; 89(1):95-104. PubMed ID: 26489025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
    Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
    Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment.
    Kim CH; Takai E; Zhou H; von Stechow D; Müller R; Dempster DW; Guo XE
    J Bone Miner Res; 2003 Dec; 18(12):2116-25. PubMed ID: 14672346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.
    Allen MR; Newman CL; Chen N; Granke M; Nyman JS; Moe SM
    Osteoporos Int; 2015 Mar; 26(3):977-85. PubMed ID: 25466530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
    Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
    Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?
    Ferreira JC; Ferrari GO; Neves KR; Cavallari RT; Dominguez WV; Dos Reis LM; Graciolli FG; Oliveira EC; Liu S; Sabbagh Y; Jorgetti V; Schiavi S; Moysés RM
    PLoS One; 2013; 8(11):e79721. PubMed ID: 24236156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!
    Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N
    Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM; Schiavi SC
    Semin Dial; 2015; 28(6):578-86. PubMed ID: 26288182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone.
    Duan Y; De Luca V; Seeman E
    J Clin Endocrinol Metab; 1999 Feb; 84(2):718-22. PubMed ID: 10022443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.